203 related articles for article (PubMed ID: 12399962)
1. Leukemic dendritic cells: potential for therapy and insights towards immune escape by leukemic blasts.
Mohty M; Olive D; Gaugler B
Leukemia; 2002 Nov; 16(11):2197-204. PubMed ID: 12399962
[TBL] [Abstract][Full Text] [Related]
2. Induction of leukemia-specific cytotoxic response by cross-presentation of late-apoptotic leukemic blasts by autologous dendritic cells of nonleukemic origin.
Spisek R; Chevallier P; Morineau N; Milpied N; Avet-Loiseau H; Harousseau JL; Meflah K; Gregoire M
Cancer Res; 2002 May; 62(10):2861-8. PubMed ID: 12019165
[TBL] [Abstract][Full Text] [Related]
3. Employing the immunological synapse in AML: development of leukemic dendritic cells for active specific immunization.
Houtenbos I; Westers TM; Ossenkoppele GJ; van de Loosdrecht AA
Immunobiology; 2005; 210(2-4):249-57. PubMed ID: 16164032
[TBL] [Abstract][Full Text] [Related]
4. Dendritic cells (DCs) can be successfully generated from leukemic blasts in individual patients with AML or MDS: an evaluation of different methods.
Kremser A; Dressig J; Grabrucker C; Liepert A; Kroell T; Scholl N; Schmid C; Tischer J; Kufner S; Salih H; Kolb HJ; Schmetzer H
J Immunother; 2010; 33(2):185-99. PubMed ID: 20139775
[TBL] [Abstract][Full Text] [Related]
5. Dendritic cell vaccines in acute leukaemia.
Duncan C; Roddie H
Best Pract Res Clin Haematol; 2008 Sep; 21(3):521-41. PubMed ID: 18790453
[TBL] [Abstract][Full Text] [Related]
6. The quality and quantity of leukemia-derived dendritic cells from patients with acute myeloid leukemia and myelodysplastic syndrome are a predictive factor for the lytic potential of dendritic cells-primed leukemia-specific T cells.
Grabrucker C; Liepert A; Dreyig J; Kremser A; Kroell T; Freudenreich M; Schmid C; Schweiger C; Tischer J; Kolb HJ; Schmetzer H
J Immunother; 2010 Jun; 33(5):523-37. PubMed ID: 20463595
[TBL] [Abstract][Full Text] [Related]
7. The 'kiss of death' by dendritic cells to cancer cells.
Chan CW; Housseau F
Cell Death Differ; 2008 Jan; 15(1):58-69. PubMed ID: 17948029
[TBL] [Abstract][Full Text] [Related]
8. Antigen presentation by dendritic cells and their significance in antineoplastic immunotherapy.
Bodey B; Siegel SE; Kaiser HE
In Vivo; 2004; 18(1):81-100. PubMed ID: 15011756
[TBL] [Abstract][Full Text] [Related]
9. Can leukemia-derived dendritic cells generate antileukemia immunity?
Rosenblatt J; Avigan D
Expert Rev Vaccines; 2006 Aug; 5(4):467-72. PubMed ID: 16989627
[TBL] [Abstract][Full Text] [Related]
10. Cancer immunotherapy by fusions of dendritic cells and tumor cells.
Koido S; Hara E; Homma S; Ohkusa T; Gong J; Tajiri H
Immunotherapy; 2009 Jan; 1(1):49-62. PubMed ID: 20635973
[TBL] [Abstract][Full Text] [Related]
11. Dendritic cell-tumor cell hybrids enhance the induction of cytotoxic T lymphocytes against murine colon cancer: a comparative analysis of antigen loading methods for the vaccination of immunotherapeutic dendritic cells.
Yasuda T; Kamigaki T; Nakamura T; Imanishi T; Hayashi S; Kawasaki K; Takase S; Ajiki T; Kuroda Y
Oncol Rep; 2006 Dec; 16(6):1317-24. PubMed ID: 17089056
[TBL] [Abstract][Full Text] [Related]
12. Impaired antigen presentation in neoplasia: basic mechanisms and implications for acute myeloid leukemia.
van Luijn MM; van den Ancker W; Chamuleau ME; Ossenkoppele GJ; van Ham SM; van de Loosdrecht AA
Immunotherapy; 2010 Jan; 2(1):85-97. PubMed ID: 20635891
[TBL] [Abstract][Full Text] [Related]
13. Dendritic type, accessory cells within the mammalian thymic microenvironment. Antigen presentation in the dendritic neuro-endocrine-immune cellular network.
Bodey B; Bodey B; Kaiser HE
In Vivo; 1997; 11(4):351-70. PubMed ID: 9292303
[TBL] [Abstract][Full Text] [Related]
14. Dendritic cells as vectors for immunotherapy of tumor and its application for gastric cancer therapy.
Wu Y; Wang L; Zhang Y
Cell Mol Immunol; 2004 Oct; 1(5):351-6. PubMed ID: 16285894
[TBL] [Abstract][Full Text] [Related]
15. The boosting effect of co-transduction with cytokine genes on cancer vaccine therapy using genetically modified dendritic cells expressing tumor-associated antigen.
Ojima T; Iwahashi M; Nakamura M; Matsuda K; Naka T; Nakamori M; Ueda K; Ishida K; Yamaue H
Int J Oncol; 2006 Apr; 28(4):947-53. PubMed ID: 16525645
[TBL] [Abstract][Full Text] [Related]
16. Preparation of fully activated dendritic cells capable of priming tumor-specific cytotoxic T lymphocytes in patients with metastatic cancer using penicillin-killed streptococcus pyogenes (OK432) and anti-CD40 antibody.
Kontani K; Teramoto K; Ozaki Y; Sawai S; Tezuka N; Ishida H; Kajino K; Fujino S; Yamauchi A; Taguchi O; Kannagi R; Yokomise H; Ogasawara K
Oncol Rep; 2007 Apr; 17(4):895-902. PubMed ID: 17342333
[TBL] [Abstract][Full Text] [Related]
17. Dendritic cell-based vaccines: clinical applications in breast cancer.
Gelao L; Criscitiello C; Esposito A; De Laurentiis M; Fumagalli L; Locatelli MA; Minchella I; Santangelo M; De Placido S; Goldhirsch A; Curigliano G
Immunotherapy; 2014; 6(3):349-60. PubMed ID: 24762078
[TBL] [Abstract][Full Text] [Related]
18. Induction of G250-targeted and T-cell-mediated antitumor activity against renal cell carcinoma using a chimeric fusion protein consisting of G250 and granulocyte/monocyte-colony stimulating factor.
Tso CL; Zisman A; Pantuck A; Calilliw R; Hernandez JM; Paik S; Nguyen D; Gitlitz B; Shintaku PI; de Kernion J; Figlin R; Belldegrun A
Cancer Res; 2001 Nov; 61(21):7925-33. PubMed ID: 11691814
[TBL] [Abstract][Full Text] [Related]
19. Induction of anti-leukemic cytotoxic T lymphocytes by fusion of patient-derived dendritic cells with autologous myeloblasts.
Gong J; Koido S; Kato Y; Tanaka Y; Chen D; Jonas A; Galinsky I; DeAngelo D; Avigan D; Kufe D; Stone R
Leuk Res; 2004 Dec; 28(12):1303-12. PubMed ID: 15475072
[TBL] [Abstract][Full Text] [Related]
20. RNA loading of leukemic antigens into cord blood-derived dendritic cells for immunotherapy.
Hsu AK; Kerr BM; Jones KL; Lock RB; Hart DN; Rice AM
Biol Blood Marrow Transplant; 2006 Aug; 12(8):855-67. PubMed ID: 16864056
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
